DOCSLIB.ORG

NEWS 02 2020 ENG.Qxp Layout 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Polymers and fluorescence Balance of power 360° drinking water analysis trilogy Fluorescence spectroscopy LCMS-8060NX: performance of industrial base polymers and robustness without Automatic, simultaneous and compromising sensitivity rapid analysis of pesticides and speed CONTENT APPLICATION »Plug und Play« disease screening solution? – The MALDI-8020 in screening for Sickle Cell Disease 4 Customized software solutions for any measurement – Macro programming for Shimadzu UV-Vis and FTIR 8 Ensuring steroid-free food supplements – Identification of steroids in pharmaceuticals and food supplements with LCMS-8045 11 MSn analysis of nonderivatized and Mtpp-derivatized peptides – Two recent studies applying LCMS-IT-TOF instruments 18 Polymers and fluorescence – Part 2: How much fluorescence does a polymer show during quality control? 26 PRODUCTS The balance of power – LCMS-8060NX balances enhanced performance and robustness 7 360° drinking water analysis: Episode 2 – Automatic, simul- taneous and rapid analysis of pesticides in drinking water by online SPE and UHPLC-MS/MS 14 Versatile testing tool for the automotive industry – Enrico Davoli with the PESI-MS system (research-use only [RUO] instrument) New HMV-G3 Series 17 No more headaches! A guide to choosing the perfect C18 column 22 Validated method for monoclonal antibody drugs – Assessment of the nSMOL methodology in Global solution through the validation of bevacizumab in human serum 24 global collaboration LATEST NEWS Global solution through global collaboration – Shimadzu Cancer diagnosis: Shimadzu innovation centers as innovation centers as a partner of scientific research 2 a partner of scientific research MARKETS eginning with one man in Kyoto, Japan, in 1875, the Chemical, Petrochemical, Shimadzu Corporation Biofuel and Energy B now has more than 10,000 em - Clinical ployees worldwide working under the company’s philosophy, “con- Environment tributing to society through sci- ence and technology.” For its Food, Beverages, Agriculture next generation of scientific excel- lence, Shimadzu has established Pharmaceutical Shimadzu Innovation Centers (SICs) across the globe, with the Plastics and Rubber European Innovation Center (EUIC) opening in 2017 in Duis - Automotive burg, Germany. Silvia Giordano and Enrico Davoli in front of the Mario Negri Institute, Milan SHIMADZU NEWS 2/2020 LATEST NEWS Based on the growing network 2018). In the project between England, where EUIC is support- The information including affili- Shimadzu has nurtured since its Davoli and Shimadzu, AI is ing Ph.D. grants for three years. ates and titles of the persons in arrival in Europe in 1968, the trained to analyze a specimen from this article are current as of the EUIC has worked on over a PESI-MS data without any histol- Shimadzu believes that no matter time of interviewing (December dozen on going projects that aim ogy or other laborious prepara- the excellence of its instruments, 2018). to change how societies preserve tion. AI will output a binary deci- the primary goal of its SICs is to food, practice medicine, and pro- sion – normal or cancer – with a benefit society. SICs therefore All the instruments in this article tect the environment. Here we statistical probability. The whole view their research collaborations are research-use only (RUO) introduce a project between EUIC process takes no more than two as academic partnerships that instruments and not for use in and an academic institution that minutes from the time the surgeon never compromise academic inde- diagnostic procedures. Shimadzu will advance cancer treatment. acquires the specimen to the AI pendence, encouraging research is an analytical equipment pro - decision. publications and supporting aca- vider and in certain regions, Research to improve demic education. including the USA, Shimadzu cancer detection After Takeda and Shimadzu had shown the effectiveness of this There is no doubt who proposed approach in Japan, the question to collaborate on the cancer proj- lingering was whether it could ect between Shimadzu and Dr. extrapolate to other countries, Enrico Davoli at the Mario Negri since the AI was originally trained Institute for Pharmacological with data from Japanese speci- Research in Milan, Italy, and the mens. That was when Shimadzu first president of the Italian Mass contacted Davoli, asking if he Spectrometry Society. After its could acquire tissue samples from successful collaboration with Italian hospitals. Davoli was very Professor Sen Takeda of Yamana - excited to take part. shi University, Japan, to study a new system that combines arti - “For a researcher, having a proto- ficial intelligence (AI) with probe type and the first to try something electrospray ionization mass spec- is a desire your whole life. The trometry (PESI-MS) to enhance instrument is brand new. The research-based detection of cancer approach is brand new. It was a cells of the liver (Yoshimura et very good opportunity,” he said. al., 2012), Shimadzu proposed to do the same with Davoli in Eu - The early results are promising, rope. and Davoli is extending his collec- tion to samples for other solid Hepatocellular carcinomas are tumors with funding from a leading cause of cancer death. Shimadzu. “Our plan is to work Common treatment involves with other European nations to resecting the cancer cells, but test PESI-MS on other popula- there is argument in the field on tions,” he says, adding that EUIC just how much healthy tissue has been instrumental at building Prof. Sen Takeda of University of Yamanashi at Shimadzu Global Innovation Summit 2017 taken in the resection is best for the continental research network. patient survival, with some re- The success of SICs is built on products may be regulated as for searchers arguing a small buffer Working like an academic new ideas, which is why our research purposes only. If you zone that removes healthy tissue partner teams are always in consultation have questions on approved use of is acceptable and others arguing with university researchers to a Shimadzu device, please contact nothing but cancerous tissue In this way, SICs can be viewed learn about scientific problems your regional office. should be removed. During the as a hybrid of industry and acade- that Shimadzu innovation can operation, the surgeon will pass a mia. All SICs aim to create new help solve. It is also why SICs References specimen to a pathologist who commercial markets, but explains build research networks, having Kudo, M. (2018). Management of Hepato - will perform histology to deter- Dr. Ann-Christin Niehoff, EUIC introduced Davoli to Takeda. cellular Carcinoma in Japan as a World- mine whether more resection is Product Manager of Imaging, mar- Takeda was invited to speak at Leading Model. Liver Cancer 7, 134-147. needed. Each specimen takes kets do not only grow from eco- our hosting event, Global Inno - about 30 minutes to prepare and nomic need, but also training vation Summit 2017 in Kyoto, Yoshimura, K., Chen, L.C., Mandal, analyze, which not only cause expertise. where he got to meet our other M.K., Nakazawa, T., Yu, Z., Uchiyama, higher costs, but also the likeli- partners in academia as well and T., Hori, H., Tanabe, K., Kubota, T., Fujii, hood of infection. “More than 90 % of Ph.D. chem - share their latest findings in ana- H., et al. (2012). Analysis of renal cell carci- ists do not stay in academia. We lytical research. noma as a first step for developing mass New science for our help build their career,” she says, spectrometry-based diagnostics. J Am Soc partners which is why Shimadzu funds By “contributing to society Mass Spectrom 23, 1741-1749. Ph.D. students and will even be through science and technology”, Japan ranks near the top of patient co-investigators on grants. Exam - Shimadzu and its SICs want to outcomes for liver cancer, in large ples include collaborative projects translate academic research into part because of Japan’s innovative at Limoges Hospital, France, and scientific solutions for some of the diagnostic technologies (Kudo, the University College London, world’s greatest challenges. SHIMADZU NEWS 2/2020 3 APPLICATION »Plug und Play« disease screening solution? The MALDI-8020 in screening for Sickle Cell Disease 3D illustration of sickle cell n 2006, the World Health Assembly passed a resolution I recognizing the Sickle Cell Disease (SCD) as a public health priority and called on countries to tackle the illness. This resolution was also adopted by the United Nations in 2009. In this context, numerous screening programs have been set up in many labora- tories around the world. SCD is a group of inherited red blood cell disorders. It is caused Figure 1: Workflow of automated screening 4 SHIMADZU NEWS 2/2020 APPLICATION ants and HbS homozygotes. The meet the criteria of automation, Resolution is an extremely second level is based on a second sensitivity, resolution, robustness, important criterion in standard reference method and is speed of analysis, resistance to the analyses of hemoglo- used to confirm the first results. high analytical rates and ease of binopathies use. Screening for hemoglobinopathies Due to abnormal hemoglobin, can be performed with newborns, Through the implementation of SCD arises from mutations in the in order to ensure early care for screening for sickle cell disease, hemoglobin beta gene (HbS) in children. This care at an early age Biomaneo company has shown which the glutamic acid is substi- enables a considerable increase in that the MALDI-8020 benchtop tuted by valine at position 6, life expectancy. The second option mass-spectrometer meets the qual- resulting in 30 Da lowering of the of screening can be carried out in ity criteria mentioned above and mass. The first NeoSickle solution young adults or adults in the case makes the use of MALDI-MS in is based on the whole protein of primary prevention, enabling laboratories easier, convenient and analysis which needs a sufficient Figure 2: Specific support for Fleximass people to know their status of fast.
Recommended publications
  • THIORIDAZINE Thioridazinum

    THIORIDAZINE Thioridazinum

    EUROPEAN PHARMACOPOEIA 5.8 Thioridazine Detection: spectrophotometer at 240 nm. C. R = CO-C2H5 : testosterone propionate, Injection: 20 µl of the test solution and reference β D. R = CO-CH(CH3)2 : 3-oxoandrost-4-en-17 -yl solutions (a) and (b). 2-methylpropanoate (testosterone isobutyrate), Run time: twice the retention time of testosterone β isocaproate. E. R = CO-[CH2]4-CH3 : 3-oxoandrost-4-en-17 -yl hexanoate (testosterone caproate), Identification of impurities: use the chromatogram supplied with testosterone isocaproate for system suitability CRS F. R = CO-[CH2]5-CH3 : testosterone enantate, and the chromatogram obtained with reference solution (a) toidentifythepeaksduetoimpuritiesA,B,C,D,E,FandG. Relative retention with reference to testosterone isocaproate (retention time = about 14 min): impurity A = about 0.2; impurity B = about 0.4; impurity C = about 0.5; impurity D = about 0.7; impurity G = about 0.8; impurity E = about 1.1; impurity F = about 1.4. System suitability: reference solution (a): G. 3-oxoandrost-4-en-17α-yl 4-methylpentanoate — peak-to-valley ratio: minimum 2.5, where Hp =height abovethebaselineofthepeakduetoimpurityEand (epitestosterone isocaproate). Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to testosterone isocaproate. 07/2007:2005 Limits: — impurities A, B, C, D, E, F, G:foreachimpurity,notmore THIORIDAZINE than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); Thioridazinum — unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent); — total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent); — disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) C H N S M 370.6 (0.05 per cent).
  • A Simple Toxicological Analysis of Anabolic Steroid Preparations from the Black Market

    A Simple Toxicological Analysis of Anabolic Steroid Preparations from the Black Market

    Ann Toxicol Anal. 2012; 24(2): 67-72 Available online at: c Société Française de Toxicologie Analytique 2012 www.ata-journal.org DOI: 10.1051/ata/2012011 Original article / Article original A simple toxicological analysis of anabolic steroid preparations from the black market Analyse toxicologique simple de stéroïdiens anabolisants provenant de marchés parallèles Manuela Pellegrini, Maria Concetta Rotolo, Rita Di Giovannadrea, Roberta Pacifici, Simona Pichini Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Via le Regina Elena 299, 00161 Rome, Italy Abstract – Objectives: A simple and rapid gas chromatography (GC) method with mass spectrometry (MS) detection was developed for the identification and quantification of anabolic steroids in pharmaceutical preparations from the black market. Material and Methods: After a liquid-liquid extraction of pharmaceutical products at acidic, neutral and basic pH with chloroform-isopropanol (9:1, v/v), the different steroids were separated by fused silica capillary column and detected by electron impact (EI)-MS in positive ionization mode. Results and Conclusion: The assay was validated in the range from 10 mg to 250 mg/g powder preparations and 0.02 mg to 200 mg/mL liquid preparations with good determination coefficients (r2 0.99) for the calibration curves. At three concentrations spanning the linear dynamic ranges of the calibration curves, mean recoveries were always higher than 90% and intra-assay and inter-assay precision and accuracy were always better than 15%. This method was successfully applied to the analysis of 15 pharmaceutical preparations sold by illegal sources. In only two cases the content was the one reported on the labels.
  • 2,4-Dichlorophenoxyacetic Acid

    2,4-Dichlorophenoxyacetic Acid

    2,4-Dichlorophenoxyacetic acid 2,4-Dichlorophenoxyacetic acid IUPAC (2,4-dichlorophenoxy)acetic acid name 2,4-D Other hedonal names trinoxol Identifiers CAS [94-75-7] number SMILES OC(COC1=CC=C(Cl)C=C1Cl)=O ChemSpider 1441 ID Properties Molecular C H Cl O formula 8 6 2 3 Molar mass 221.04 g mol−1 Appearance white to yellow powder Melting point 140.5 °C (413.5 K) Boiling 160 °C (0.4 mm Hg) point Solubility in 900 mg/L (25 °C) water Related compounds Related 2,4,5-T, Dichlorprop compounds Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) 2,4-Dichlorophenoxyacetic acid (2,4-D) is a common systemic herbicide used in the control of broadleaf weeds. It is the most widely used herbicide in the world, and the third most commonly used in North America.[1] 2,4-D is also an important synthetic auxin, often used in laboratories for plant research and as a supplement in plant cell culture media such as MS medium. History 2,4-D was developed during World War II by a British team at Rothamsted Experimental Station, under the leadership of Judah Hirsch Quastel, aiming to increase crop yields for a nation at war.[citation needed] When it was commercially released in 1946, it became the first successful selective herbicide and allowed for greatly enhanced weed control in wheat, maize (corn), rice, and similar cereal grass crop, because it only kills dicots, leaving behind monocots. Mechanism of herbicide action 2,4-D is a synthetic auxin, which is a class of plant growth regulators.
  • Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer

    Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer

    Bipolar Androgen Therapy (BAT) in men with prostate cancer Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine, Baltimore, MD Presentation Overview • Androgen and Androgen Signaling 101 • Rationale For Bipolar Androgen Therapy (BAT) • Results from the RESTORE study testing BAT in Castration Resistant Prostate Cancer • The multi-center TRANSFORMER Trial • Future Directions • Results of BATMAN trial testing BAT as part of Intermittent Hormone Therapy strategy Testosterone Replacement Anabolic Steroids Trenbolone Acetate (Fina-Finaplix H pellets) High Dose Testosterone as Treatment for Prostate Cancer What Are Androgens? • Steroid hormone which can bind to Androgen Receptor – Testosterone, Dihydrotestosterone (DHT), DHEA, Androstenedione… • Sexual Differentiation – Needed to make a Male (Female is Default) • Primary Sex Characteristics: – Spermatogenesis – Accessory Sex Tissue Maintenance • Penis, Prostate... • Secondary Sex Characteristics: – Bone density – Muscle mass – Libido – Hair growth – Hematopoiesis What is a Steroid Hormone? Testosterone (T) Dihydrotestosterone (DHT) Estrogen How are Androgens Made? Androgen Receptor Signaling 101 Androgen Active Androgen Receptor (Testosterone) Androgen Receptor How Do Androgens Effect the Prostate Cell? NTD- Signaling Part DBD- DNA Binding Part LBD- Androgen Binding Part Cytoplasm Cell Nucleus Binds and activates genes: -Cell Growth -Cell Survival -Make prostate stuff like PSA, Acid Phosphatase, etc. DNA The Devilish Prostate • Physiologic
  • Common and Chemical Names of Herbicides Approved by the WSSA

    Common and Chemical Names of Herbicides Approved by the WSSA

    Weed Science 2010 58:511–518 Common and Chemical Names of Herbicides Approved by the Weed Science Society of America Below is the complete list of all common and chemical of herbicides as approved by the International Organization names of herbicides approved by the Weed Science Society of for Standardization (ISO). A sponsor may submit a proposal America (WSSA) and updated as of September 1, 2010. for a common name directly to the WSSA Terminology Beginning in 1996, it has been published yearly in the last Committee. issue of Weed Science with Directions for Contributors to A herbicide common name is not synonymous with Weed Science. This list is published in lieu of the selections a commercial formulation of the same herbicide, and in printed previously on the back cover of Weed Science. Only many instances, is not synonymous with the active ingredient common and chemical names included in this complete of a commercial formulation as identified on the product list should be used in WSSA publications. In the absence of label. If the herbicide is a salt or simple ester of a parent a WSSA-approved common name, the industry code number compound, the WSSA common name applies to the parent as compiled by the Chemical Abstracts Service (CAS) with compound only. CAS systematic chemical name or the systematic chemical The chemical name used in this list is that preferred by the name alone may be used. The current approved list is also Chemical Abstracts Service (CAS) according to their system of available at our web site (www.wssa.net).
  • Albany-Molecular-Research-Regulatory

    Albany-Molecular-Research-Regulatory

    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
  • COMBINED LIST of Particularly Hazardous Substances

    COMBINED LIST of Particularly Hazardous Substances

    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
  • Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye

    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye

    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Thesis Submitted to the Faculty of Science in Fulfilment of the Requirements for the Degree of Doctor in Science (Chemistry) Sander Delahaye Promotor Prof. Dr. Frédéric Lynen Leden van de lees- en examencommissie: Voorzitter: Prof. Dr. J. Martins Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent Leescommissie: Prof. Dr. K. Broeckhoven Vakgroep Chemische Ingenieurstechnieken en Industriële Scheikunde (CHIS), Faculteit Ingenieurswetenschappen, Vrije Universiteit Brussel Prof. Dr. D. Cabooter Laboratorium Farmaceutische Analyse, Faculteit Farmaceutische Wetenschappen, KU Leuven Dr. L. Balcaen Vakgroep Analytische Chemie, Faculteit Wetenschappen, UGent Examencommissie: Dr. I. Francois UPC²/SFC & Strategic Separation Technologies Business Development Manager Europe and India (Waters) Prof. Dr. K. Van Geem Vakgroep Chemische Proceskunde en Technische Chemie Faculteit Ingenieurswetenschappen en Architectuur, UGent Prof. Dr. F. Lynen Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent This research was funded by the Agency for Innovation by Science and Technology in Flanders (IWT - Vlaanderen) Table of Contents I General Introduction and Scope 1 1. General introduction . .1 2. Scope . .5 3. References . .6 II The Emergence of Packed-Column Supercritical Fluid Chromatography as an Alternative for HPLC 9 1. Introduction . 10 2. Definition of supercritical fluids . 10 3. Physico-chemical properties of supercritical fluids . 10 4. The use of supercritical fluids as extraction solvent and as mobile phase in chromatography . 15 5. SFC over the years . 16 6. Contemporary pSFC conditions and stationary phases . 17 7. Most important applications of supercritical fluid chromatography . 20 7.1. Preparative SFC applications . 20 7.2. Analytical SFC applications . 21 8. Nomenclature issues . 21 9.
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • (12) United States Patent (10) Patent No.: US 9,394,315 B2 Aicher Et Al

    (12) United States Patent (10) Patent No.: US 9,394,315 B2 Aicher Et Al

    USOO93943 15B2 (12) United States Patent (10) Patent No.: US 9,394,315 B2 Aicher et al. (45) Date of Patent: Jul.19, 2016 (54) TETRAHYDROI18NAPHTHYRIDINE 6,605,634 B2 8, 2003 Zablocki et al. SULFONAMIDE AND RELATED 6,638,960 B2 10/2003 Assmann et al. 6,683,091 B2 1/2004 Asberomet al. COMPOUNDS FOR USEAS AGONSTS OF 6,828,344 B1 12/2004 Seehra et al. RORY AND THE TREATMENT OF DISEASE 7,084, 176 B2 8, 2006 Morie et al. 7,138.401 B2 11/2006 Kasibhatla et al. (71) Applicant: Lycera Corporation, Ann Arbor, MI 7,329,675 B2 2/2008 Cox et al. 7,420,059 B2 9, 2008 O'Connor et al. (US) 7,482.342 B2 1/2009 D’Orchymont et al. 7,569,571 B2 8/2009 Dong et al. (72) Inventors: Thomas D. Aicher, Ann Arbor, MI (US); 7,696,200 B2 4/2010 Ackermann et al. Peter L. Toogood, Ann Arbor, MI (US); 7,713.996 B2 5/2010 Ackermann et al. Xiao Hu, Northville, MI (US) 7,741,495 B2 6, 2010 Liou et al. 7,799,933 B2 9/2010 Ceccarelli et al. (73) Assignee: Lycera Corporation, Ann Arbor, MI 2006,0004000 A1 1/2006 D'Orchymont et al. 2006/010O230 A1 5, 2006 Bischoff et al. (US) 2007/0010537 A1 1/2007 Hamamura et al. 2007/OO 10670 A1 1/2007 Hirata et al. (*) Notice: Subject to any disclaimer, the term of this 2007/0049556 A1 3/2007 Zhang et al. patent is extended or adjusted under 35 2007/0060567 A1 3/2007 Ackermann et al.
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel

    Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel

    253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
  • INDEX to PESTICIDE TYPES and FAMILIES and PART 180 TOLERANCE INFORMATION of PESTICIDE CHEMICALS in FOOD and FEED COMMODITIES

    INDEX to PESTICIDE TYPES and FAMILIES and PART 180 TOLERANCE INFORMATION of PESTICIDE CHEMICALS in FOOD and FEED COMMODITIES

    US Environmental Protection Agency Office of Pesticide Programs INDEX to PESTICIDE TYPES and FAMILIES and PART 180 TOLERANCE INFORMATION of PESTICIDE CHEMICALS in FOOD and FEED COMMODITIES Note: Pesticide tolerance information is updated in the Code of Federal Regulations on a weekly basis. EPA plans to update these indexes biannually. These indexes are current as of the date indicated in the pdf file. For the latest information on pesticide tolerances, please check the electronic Code of Federal Regulations (eCFR) at http://www.access.gpo.gov/nara/cfr/waisidx_07/40cfrv23_07.html 1 40 CFR Type Family Common name CAS Number PC code 180.163 Acaricide bridged diphenyl Dicofol (1,1-Bis(chlorophenyl)-2,2,2-trichloroethanol) 115-32-2 10501 180.198 Acaricide phosphonate Trichlorfon 52-68-6 57901 180.259 Acaricide sulfite ester Propargite 2312-35-8 97601 180.446 Acaricide tetrazine Clofentezine 74115-24-5 125501 180.448 Acaricide thiazolidine Hexythiazox 78587-05-0 128849 180.517 Acaricide phenylpyrazole Fipronil 120068-37-3 129121 180.566 Acaricide pyrazole Fenpyroximate 134098-61-6 129131 180.572 Acaricide carbazate Bifenazate 149877-41-8 586 180.593 Acaricide unclassified Etoxazole 153233-91-1 107091 180.599 Acaricide unclassified Acequinocyl 57960-19-7 6329 180.341 Acaricide, fungicide dinitrophenol Dinocap (2, 4-Dinitro-6-octylphenyl crotonate and 2,6-dinitro-4- 39300-45-3 36001 octylphenyl crotonate} 180.111 Acaricide, insecticide organophosphorus Malathion 121-75-5 57701 180.182 Acaricide, insecticide cyclodiene Endosulfan 115-29-7 79401